Jose Manuel Otero sold $6,606 of LXEO
Chief Operating Officer at Lexeo Therapeutics, Inc.. 1,302 shares at an average of $5.07, traded May 18, 2026, filed May 20, 2026.
Score components
- +20RoleCOO
- 0Trade size$7k at market
- 0Share of holdings soldSold 1.0% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002024096-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 18, 2026 | SOpen-market sale Common Stock | -1,302 | $5.07 | $6,606 | 130,088 | May 20, 2026 |
Related signals
Other insiders at Lexeo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $17k 3,345 shares | -1% | |
| 35Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $6,464 1,304 shares | -1% | |
| 37Weak | Lexeo Therapeutics, Inc. | Louis Edward Tamayo Chief Financial Officer | $20k 4,117 shares | -4% | |
| 45Moderate | Lexeo Therapeutics, Inc. | Narinder Pal Bhalla Chief Medical Officer | $99k 22,306 shares | -21% | |
| 50Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $116k 25,947 shares | -6% | |
| 35Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $21k 4,666 shares | -3% | |
| 37Weak | Lexeo Therapeutics, Inc. | Louis Edward Tamayo Chief Financial Officer | $21k 4,641 shares | -5% | |
| 33Weak | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $17k 3,342 shares | -1% | |
| 24Weak | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $313k 55,000 shares | -14% | |
| 41Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $65k 10,173 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.